Since 1990, helping busy clinicians master the science and art of caring for people with HIV disease.

PRN Member Menu

Due to the COVID-19 pandemic, all meetings are now via the Zoom Webinar platform.
Pre-Register Here
Please help PRN by taking the pre-meeting evaluation. These surveys are critical to the future of our programs and accreditation.
Pre-Meeting Survey
MEETING AND CME INFORMATION

PRN Meeting: June 23, 2021 Jointly provided by the Medical Society of the State of New York, at a Zoom webinar, 7:00 p.m. to 9:00 p.m (EST).

Target Audience:

Physicians, Nurse Practitioners, and Physician Assistants caring for people at risk for, or infected with HIV and/or viral hepatitis.

Course Director: James F. Braun, DO, President, Physicians' Research Network

Course Moderator: William M. Valenti, MD, Chair, Infectious Diseases Committee of the Medical Society of the State of New York

Guest Speakers and Presentations:

Liver Disease in the Face of COVID-19

Elizabeth C. Verna, MD, MSc

Frank Cardile Associate Professor of Medicine, Columbia University Medical Center
Director of Clinical Research, Columbia University Transplant Initiative
and the Transplant Clinical Research Center, New York, NY

Does COVID-19 infection contribute to liver disease? And does pre-existing liver disease affect the course of COVID-19 outcomes?  In this presentation, Elizabeth Verna addresses these important questions and also explains how the COVID-19 pandemic has impacted the care of patients with chronic liver disease including the initiatives regarding viral hepatitis elimination.

Learning Objectives:

At the completion of this educational session, participants will:
1. Understand the impact of COVID-19-related liver injury upon patient outcomes.
2. Understand whether chronic liver disease increases the risk of severe COVID-19-related illness.
3. Understand how the COVID-19 pandemic has impacted the care of patients with chronic liver disease including the initiatives regarding viral hepatitis elimination.

Inflammation, Morbidity and Mortality in Treated HIV: Roles of Asymptomatic CMV and Sex Differences

Peter W. Hunt, MD

Professor of Medicine, Division of Experimental Medicine, UCSF
Co-Director of Basic/Translational Sciences, Center for AIDS Research
San Francisco, CA

Chronic inflammation caused by herpesviruses (especially CMV) and by sex differences, leads to end-organ morbidities in HIV disease despite optimal treatment of HIV. In this presentation, Peter Hunt explores the causes and consequences of persistent immune activation in treated HIV infection, including its impact on age-related morbidity and mortality as well as HIV persistence.

Learning Objectives:

At the completion of this educational session, participants will:
1. Understand the potential impact of asymptomatic CMV and other herpesvirus replication on the inflammatory state in treated HIV infection.
2. Understand the potential contributions of CMV-associated inflammation to end-organ disease in treated HIV infection and the landscape of planned clinical trials that will shed light on these issues.
3. Understand sex differences in the inflammatory state in treated HIV infection and how they may impact morbidity risk.

Accreditation Statement: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). The Medical Society of the State of New York (MSSNY) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing Medical Education for physicians.

The Medical Society of the State of New York (MSSNY) designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement:

Dr. Braun (Planner/Course Director) has no relevant financial relationships to disclose. Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose. Dr. Elizabeth C. Verna (Presenter) has no relevant financial relationships to disclose. Dr. Verna will support her presentation and clinical recommendations with the best available evidence from the medical literature and will submit her slides in advance for adequate peer review. Dr. Peter W. Hunt (Presenter) has no relevant financial relationships to disclose. Dr. Hunt will support his presentation and clinical recommendations with the best available evidence from the medical literature and will submit his slides in advance for adequate peer review.

Financial Support:

This PRN CME activity is funded in part by unrestricted educational grants from:
Gilead Sciences; Janssen Therapeutics, a division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare

PRN Member Menu

Are you a member? If so, please log-in.

Not a member? Please register.

Have you forgotten your password?